Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-04-16FDA Approved: POSFREA — Supplemental Application (Avyxa Pharma, LLC)
The FDA approved a supplemental application for POSFREA (palonosetron) from Avyxa Pharma, LLC. The approval updates the product labeling to …
-
FDA approval · 2025-04-08FDA Approved: FOSAPREPITANT — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for fosaprepitant submitted by Mylan Institutional LLC, resulting in an updated approval of the …
-
FDA approval · 2025-03-25FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for palonosetron hydrochloride (generic) submitted by Eugia US LLC under ANDA204702, adding to t…
-
FDA approval · 2025-03-24FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for granisetron hydrochloride submitted by Eugia US LLC.
-
FDA approval · 2025-03-24FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for palonosetron hydrochloride submitted by Sagent Pharmaceuticals to support an approved indication…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-03-17FDA Approved: GRANISOL — Original Application (Intra-Sana Laboratories)
FDA approved GRANISOL (granisetron hydrochloride) through an original ANDA submission by Intra-Sana Laboratories, authorizing the generic pr…
-
FDA approval · 2024-10-25FDA Approved: FOSAPREPITANT — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for fosaprepitant filed by BluePoint Laboratories.
-
FDA approval · 2024-10-18FDA Approved: FOSAPREPITANT — Supplemental Application (BE Pharmaceuticals Inc.)
FDA approved a supplemental application for fosaprepitant submitted by BE Pharmaceuticals Inc., resulting in an updated label under the ANDA…
-
FDA approval · 2024-09-16FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved a supplemental application for SANCUSO (granisetron) submitted by Cumberland Pharmaceuticals Inc.
-
FDA approval · 2024-09-16FDA Approved: FOSAPREPITANT — Supplemental Application (Avenacy, LLC)
FDA approved a supplemental application for Fosaprepitant (fosaprepitant dimeglumine) from Avenacy, LLC.
-
FDA approval · 2024-07-08FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for a generic ondansetron hydrochloride product submitted by Fresenius Kabi USA, LLC.
-
FDA approval · 2024-05-17FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
FDA approved a supplemental application for dronabinol from Wellhouse Pharma, LLC.
-
FDA approval · 2024-03-05FDA Approved: APONVIE — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for APONVIE (aprepitant) from Heron Therapeutics, Inc., expanding its regulatory authorization.
-
FDA approval · 2024-03-05FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for CINVANTI (aprepitant) submitted by Heron Therapeutics, Inc.
-
FDA approval · 2024-01-31FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc., indicating an approved change to the generic's la…
-
FDA approval · 2024-01-05FDA Approved: DEXAMETHASONE INTENSOL — Supplemental Application (Hikma Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for DEXAMETHASONE INTENSOL from Hikma Pharmaceuticals USA, Inc., a dexamethasone product.
-
FDA approval · 2023-12-14FDA Approved: DRONABINOL — Supplemental Application (Camber Pharmaceuticals Inc)
FDA approved a supplemental application for dronabinol from Camber Pharmaceuticals Inc.
-
FDA approval · 2023-10-12FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Granisetron Hydrochloride by Bionpharma Inc., a generic antiemetic used to prevent chemotherapy-…
-
FDA approval · 2023-10-10FDA Approved: FOSAPREPITANT DIMEGLUMINE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for fosaprepitant dimeglumine (generic) from Eugia US LLC under ANDA210625.
-
FDA approval · 2023-09-26FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
FDA granted a supplemental approval for Ondansetron hydrochloride from Eugia US LLC, updating the status of this generic product. The action…
-
FDA approval · 2023-08-29FDA Approved: FOSAPREPITANT — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Fosaprepitant, filed by Fresenius Kabi USA, expanding its approved labeling.
-
FDA approval · 2023-08-25FDA Approved: PALONOSETRON — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Palonosetron hydrochloride from Apotex Corp., confirming its generic use. Palonosetron is used t…
-
FDA approval · 2023-08-22FDA Approved: FOCINVEZ — Original Application (Steriscience Specialties Private Limited)
FDA approved FOCINVEZ (fosaprepitant dimeglumine) from Steriscience Specialties Private Limited through an Original Application for preventi…
-
FDA approval · 2023-08-14FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' palonosetron hydrochloride generic under an Original Application for preventing postoperative nausea …
-
FDA approval · 2023-07-25FDA Approved: FOSAPREPITANT DIMEGLUMINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Fosaprepitant Dimeglumine from Hikma Pharmaceuticals USA Inc. under the ANDA program. The submis…